1. Home
  2. SONM vs BTAI Comparison

SONM vs BTAI Comparison

Compare SONM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonim Technologies Inc.

SONM

Sonim Technologies Inc.

HOLD

Current Price

$5.90

Market Cap

6.5M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$2.04

Market Cap

49.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONM
BTAI
Founded
1999
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
49.2M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
SONM
BTAI
Price
$5.90
$2.04
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$32.80
AVG Volume (30 Days)
43.1K
574.6K
Earning Date
10-31-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,109,000.00
$752,000.00
Revenue This Year
$127.68
N/A
Revenue Next Year
N/A
$416.40
P/E Ratio
N/A
N/A
Revenue Growth
4.17
N/A
52 Week Low
$4.75
$1.17
52 Week High
$114.84
$9.26

Technical Indicators

Market Signals
Indicator
SONM
BTAI
Relative Strength Index (RSI) 41.07 48.39
Support Level $5.85 $1.82
Resistance Level $6.86 $2.30
Average True Range (ATR) 0.67 0.18
MACD -0.17 0.03
Stochastic Oscillator 29.38 37.30

Price Performance

Historical Comparison
SONM
BTAI

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: